Antibiotic resistance in gram negative bacteria is increasing worldwide in both outpatients as well as hospitalized patients. Most bacterial isolates carry resistance determinants for extended spectrum beta lactamases (ESBL) production on plasmids that can easily spread from organism to organism. This study was conducted to compare the rate of detection of ESBL positive organisms by different methods, to use the clinical and laboratory standard institute (CLSI) detection methods for detecting ESBLs in bacteria other than Enterobacteriaceae and genotypic characterization of these ESBL strains. A total of 100 non repetitive gram negative isolates, which were resistant to ceftriaxone, cefotaxime or ceftazidime were only included in the study. All the 100 screen test positive isolates were tested for ESBL production using the different phenotypic detection methods. Molecular characterization of the strains was done at the Rajiv Gandhi Centre for Biotechnology, Trivandrum. Among total 100 gram negative isolates which were 3 rd generation cephalosporin resistant, 79(79%) were ESBL positive by using CLSI phenotypic confirmatory test. Of this 79%, majority of isolates were detected in blood samples (38%). Of the different methods employed, E-test detected additional 3% and 11% ESBL positive Escherichia coli and Klebsiella pneumoniae respectively. CLSI phenotypic confirmatory test also detected ESBL positive Pseudomonas sp, Acinetobacter sp and Enterobacter cloacae. The genotype characterization of 52 isolates showed 29 with CTX-M and 13 with TEM genes. Thus, the study shows a significant rate of ESBL production in gram negative bacteria emphasizing the need for enhanced infection control and antibiotic stewardship programs to limit the spread of these organisms.
Extended spectrum beta lactamases (ESBLs) are beta-lactamases that hydrolyze extended-spectrum cephalosporins with an oxyimino side chain. These cephalosporins include cefotaxime, ceftriaxone, and ceftazidime, as well as the oxyimino-monobactam aztreonam 1, 2 3 . Gram negative isolates were screened for potential ESBL producers by Kirby-Bauer disc diffusion method on Mueller-Hinton Agar (MHA). Isolates that showed resistance to one or all of the following antibiotics were considered as potential ESBL producers and were only included in the study ( Table I ). All resistance breakpoints were according to clinical and laboratory standard institute (CLSI) guidelines (document M100-S20). 4 Confirmation of ESBL production: All 100 screen positive isolates were then subjected for confirmatory test by CLSI phenotypic confirmatory test (cephalosporin/clavulanate combination disc test) (PCT)- (Figure I) , double disc diffusion test (DDST)-( Figure II ) and Etest-( Figure III) 
Results:
Maximum number of patients was in the elderly age group of >50yrs (47%) and majority were males (54%). Of the 100 study samples, majority were cases of sepsis (24%). 21% of cases were urinary tract infections while abscess contributed to 12% of cases. Isolates from blood samples constituted 39% followed by urine (22%). Of the 22 urine isolates, 20 were ESBL producers (90%), while only 30 (76%) out of 39 blood isolates were ESBL producers. Of this 20 ESBL positive urine isolates, 13 (65%) were from catheterized samples.
Of the 100 ESBL screen positive isolates, 79 isolates were detected as ESBL producers by CLSI phenotypic confirmatory test. 
Discussion:
Understanding the impact of drug resistance is of critical importance as the changing trend of antibiotic resistance has a large impact on the empirical therapy of different infections 5 . Antibiotic resistance varies according to geographic locales and is directly proportional to the use and misuse of antibiotics. The prevalence of ESBL production among Enterobacteriaceae varies greatly from country to country and among the institutions within the country. From our study, ESBLs detected among 3 rd generation cephalosporin resistant gram negative bacteria was found to be 79%. High percentage of ESBL s were reported by Jain Amitha et al (86%) 6 and Rodrigues et al (53%) 7 . Of the total 79 ESBL positive isolates majority was from blood sample (38%) followed by urine (25%). Of the 22 urine isolates, 20 were ESBL producers (90%). Of this 20 ESBL positive urine isolates, 13 (65%) were from catheterized samples. In a study by Khalid Mubarak et al, urine was found to be the major source of ESBL isolates 8 . Kader et al have reported a high incidence of ESBL production among catheterized patients.
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Microbial profile: In the present study, 40.5% of ESBL producers were E.coli while ESBL positive Klebsiella pneumoniae was 34.1% (Table II) . However, most of the past studies have shown ESBL producing Klebsiella strains to be more prevalent than ESBL producing E.coli. In accordance with our study, similar results were obtained by Ananthakrishnan et al 10 (E.coli 56.2%, Klebsiella pneumoniae 21.8%) and B Jorn Blomberg et al 11 (E.coli 25%, Klebsiella pneumoniae 17%) with highest percentage of ESBLs among E.coli. ESBL production has also been found in other members of the Enterobacteriaceae family 12 . CLSI guidelines which are only for E.coli, Klebsiella pneumoniae, and Proteus mirabilis, were extended for other gram negative bacteria in the present study. We observed ESBL production in Pseudomonas aeruginosa (10.1%), Acinetobacter baumanii (6.3%), Enterobacter cloacae (5%) and Proteus mirabilis (3.7%) also (Table II) . In Pseudomonas aeruginosa, ESBL production is less as compared to Enterobacteriaceae, because their resistance is mediated by various other mechanisms such as the production of metallo-betalactamases, lack of drug penetration due to mutations in the porins and the loss of certain outer membrane proteins and efflux pumps.
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Different methods of ESBL detection:
In the present study, presence of ESBLs was determined with CLSI phenotypic confirmatory test (PCT), double disc diffusion test (DDST) and E-test (Table-III) . PCT detected 79 (79%) isolates, DDST detected 52 (52%) isolates and Etest detected 75(75%) isolates. Thus a higher rate of ESBL detection was found with CLSI phenotypic confirmatory test. In this study, for E.coli, PCT detected 86.4% of ESBLs. DDST detected 62.1% of ESBLs (Table-III) . Additional 24% cases were detected by CLSI phenotypic confirmatory test than DDST method. In Klebsiella pneumoniae, PCT detected 75% of ESBLs. DDST detected 63.8% of ESBLs. Additional 12 % cases were detected by CLSI phenotypic confirmatory test than DDST method. Thus in this study, it was observed that ESBL production among E.coli and Klebsiella pneumoniae isolates were more frequently detected by the combination disc (PCT) method than the double disc approximation test. The clinical laboratory standards institute (CLSI) also recommends the use of the combination disc method for the phenotypic confirmation of ESBL production among Enterobacteriaceae 4 .Umadevi S et al from Pondicherry also observed in their study that ESBL production among E. coli and Klebsiella pneumoniae isolates were more frequently detected by the combination disc method than the double disk approximation test.
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E-test detected additional 3% and 11% of ESBL cases of E.coli and Klebsiella pneumoniae respectively than CLSI phenotypic confirmatory test (Table III) . In a study by Martin G. Cormican, Steven A. Marshall and Ronald N. Jones, similar results were obtained with higher sensitivity for E-test for ESBL detection in E.coli and Klebsiella sp. 16 In the present study, PCT was superior in detection of ESBLs in case of Pseudomonas aeruginosa and Acinetobacter baumanii than DDST and E-test (Table III) . However, CLSI recommends the double disc approximation method for testing ESBL production among the Pseudomonas aeruginosa isolates. 4 Failure to detect the better performance of the double disc approximation test as compared to the combination disc method for the detection of ESBL production among the Pseudomonas aeruginosa in this study could be due to the relatively small number of isolates which were tested. Even though, the phenotypic confirmatory tests are also highly sensitive and specific, there are a number of instances when these tests may be falsely positive or falsely negative. False positives may occur if the isolate lacks ESBL but produces an excess of TEM-1 or SHV-1. On the other hand, isolates harbouring both ESBLs and AmpC type β-lactamases may result in false-negative results.
Molecular characterization of ESBLs:
Of the 52 ESBL positive isolates subjected for polymerase chain reaction to look for the presence of blaTEM and blaCTX-M genes, only 32 (61.5%) could be typed for one or more genes ( Table IV) . The negative amplification in the remaining isolates may be due to presence of other ESBL genes, which were not explored further. Twenty nine isolates (55.7%) were positive for CTX-M gene and thirteen isolates (25%) positive for TEM gene. Ten isolates showed the presence of both CTX-M and TEM genes. The blaCTX-M was the most common and was present either alone or in combination with other ESBL type(s). These findings support the hypothesis that CTX-M is emerging as the dominant ESBL type in clinical isolates. 3 Pournaraset al 17 reported 87 % prevalence of CTX-M enzyme among ESBL producers in a tertiary care hospital of Greece. Data from the last 10 years establishes CTX-M genotype as the predominant ESBL in Europe and East Asia. Another study by Jemima and Varghese from Chennai found that 15.83% of ESBL positive isolates had blaCTX-M gene 18 .They also noted that among those CTX-M producing isolates, CTX-M-1gene was positive in 47.3% isolates. The drawback of the present study is that the sample size was small and we were unable to do molecular characterization for all the isolates.
Conclusions:
The rise of antibiotic resistance emphasizes the importance of judicious use of antibiotics. Although infection control procedures continue to play a central role, changes in antibiotic policy may play an even greater role in this setting. The regular detection of ESBLs by standard detection methods should be carried out in every lab where molecular methods cannot be performed, as genotyping is not more informative for the treatment. Patients' culture and sensitivity report must state that the isolate is a suspected or proven ESBL producer and also include a note stating that ESBL production may predict therapeutic failure with penicillins, aztreonam and all cephalosporins (except cephamycins), irrespective of their in vitro susceptibility.
